HIMS Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 3.34% compared to Hims & Hers Health, Inc.'s net margin of 20.83%. Hims & Hers Health, Inc.'s return on equity of 23.68% beat Johnson & Johnson's return on equity of 34.46%.

Hims & Hers Health, Inc. has a consensus price target of $24.00, signalling upside risk potential of 24.57%. On the other hand Johnson & Johnson has an analysts' consensus of $241.71 which suggests that it could grow by 0.17%. Given that Hims & Hers Health, Inc. has higher upside potential than Johnson & Johnson, analysts believe Hims & Hers Health, Inc. is more attractive than Johnson & Johnson.

Hims & Hers Health, Inc. has a beta of 2.321, which suggesting that the stock is 132.056% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.337, suggesting its less volatile than the S&P 500 by 66.29%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.16% to investors and pays a quarterly dividend of $1.30 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hims & Hers Health, Inc. quarterly revenues are $617.8M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Hims & Hers Health, Inc.'s net income of $20.6M is lower than Johnson & Johnson's net income of $5.1B. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 36.95x while Johnson & Johnson's PE ratio is 22.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 2.05x versus 6.29x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 3.34% compared to Hims & Hers Health, Inc.'s net margin of 34.4%. Hims & Hers Health, Inc.'s return on equity of 23.68% beat Eli Lilly & Co.'s return on equity of 104.39%.

Hims & Hers Health, Inc. has a consensus price target of $24.00, signalling upside risk potential of 24.57%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,209.21 which suggests that it could grow by 26.84%. Given that Eli Lilly & Co. has higher upside potential than Hims & Hers Health, Inc., analysts believe Eli Lilly & Co. is more attractive than Hims & Hers Health, Inc..

Hims & Hers Health, Inc. has a beta of 2.321, which suggesting that the stock is 132.056% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.45%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.65% to investors and pays a quarterly dividend of $1.73 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hims & Hers Health, Inc. quarterly revenues are $617.8M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Hims & Hers Health, Inc.'s net income of $20.6M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 36.95x while Eli Lilly & Co.'s PE ratio is 43.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 2.05x versus 13.64x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 3.34% compared to Hims & Hers Health, Inc.'s net margin of -121.83%. Hims & Hers Health, Inc.'s return on equity of 23.68% beat Moderna, Inc.'s return on equity of -29.19%.

Hims & Hers Health, Inc. has a consensus price target of $24.00, signalling upside risk potential of 24.57%. On the other hand Moderna, Inc. has an analysts' consensus of $45.15 which suggests that it could fall by -13.34%. Given that Hims & Hers Health, Inc. has higher upside potential than Moderna, Inc., analysts believe Hims & Hers Health, Inc. is more attractive than Moderna, Inc..

Hims & Hers Health, Inc. has a beta of 2.321, which suggesting that the stock is 132.056% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.331, suggesting its more volatile than the S&P 500 by 33.144%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Hims & Hers Health, Inc. quarterly revenues are $617.8M, which are smaller than Moderna, Inc. quarterly revenues of $678M. Hims & Hers Health, Inc.'s net income of $20.6M is higher than Moderna, Inc.'s net income of -$826M. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 36.95x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 2.05x versus 10.80x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Teladoc Health, Inc. has a net margin of 3.34% compared to Hims & Hers Health, Inc.'s net margin of -3.92%. Hims & Hers Health, Inc.'s return on equity of 23.68% beat Teladoc Health, Inc.'s return on equity of -14.07%.

Hims & Hers Health, Inc. has a consensus price target of $24.00, signalling upside risk potential of 24.57%. On the other hand Teladoc Health, Inc. has an analysts' consensus of $7.09 which suggests that it could grow by 33.69%. Given that Teladoc Health, Inc. has higher upside potential than Hims & Hers Health, Inc., analysts believe Teladoc Health, Inc. is more attractive than Hims & Hers Health, Inc..

Hims & Hers Health, Inc. has a beta of 2.321, which suggesting that the stock is 132.056% more volatile than S&P 500. In comparison Teladoc Health, Inc. has a beta of 2.074, suggesting its more volatile than the S&P 500 by 107.368%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teladoc Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Teladoc Health, Inc. pays out -- of its earnings as a dividend.

Hims & Hers Health, Inc. quarterly revenues are $617.8M, which are smaller than Teladoc Health, Inc. quarterly revenues of $642.3M. Hims & Hers Health, Inc.'s net income of $20.6M is higher than Teladoc Health, Inc.'s net income of -$25.1M. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 36.95x while Teladoc Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 2.05x versus 0.36x for Teladoc Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.